UCB S.A.: Myasthenia Gravis trials

The registry lists 18 Myasthenia Gravis studies with UCB S.A. as lead sponsor. 6 are open to participants now and 9 have results posted.

Phase 1 1Phase 2 4Phase 3 14Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07465289Phase 3
• A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07463521Phase 3
• Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisRecruitingNCT07246564Phase 4
• Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Phase 1
• An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisEnrolling by invitationNCT06435312Phase 3
• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisRecruitingNCT06055959Phase 2/3
• A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia GravisCompletedNCT06471361Phase 3Results posted
• A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)CompletedNCT05681715Phase 3Results posted
• An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 InhibitorsCompletedNCT05514873Phase 3Results posted
• A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisCompletedNCT04650854Phase 3Results posted
• A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedNCT04124965Phase 3Results posted
• Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedNCT04115293Phase 3Results posted
• A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedNCT03971422Phase 3Results posted
• Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia GravisCompletedNCT03315130Phase 2Results posted
• Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia GravisCompletedNCT03052751Phase 2Results posted
• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisActive, not recruitingNCT06540144Phase 3
• A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisCompletedNCT06149559Phase 2/3
• Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedNCT04225871Phase 3